Introduction
NF-B/Rel transcription factors play a central mediatory role in immune and inflammatory responses as well as in cell proliferation and apoptosis. [1] [2] [3] Dysregulation of the NF-B system may lead to gene expression patterns involved in tumor growth, invasion and metastasis. 4 A constitutive NF-B activation has been detected in hematopoietic malignancies such as Hodgkin's disease (HD) or acute lymphoblastic leukemia (ALL) as well as in several types of solid tumor. [4] [5] [6] NF-B assumes a dimeric complex most frequently assembled from the subunits RelA (p65) and p50, but also p52, c-Rel and RelB. 1, 2 The dimer is trapped in the cytosol by inhibitory IB proteins, including IB-␣, -␤ and -⑀. 1, 7, 8 Inhibitory functions have also been demonstrated for the NF-B precursor proteins p105 and p100. 2, 9 The genes for the NF-B subunits as well as the IB proteins including Bcl-3 are all located at sites of recurrent translocation and genomic rearrangement in human cancer. 10 Furthermore, a marked homology of the amino termini of both p50 and p65 with the viral oncoprotein v-Rel was found. 4 NF-B activity is modulated by various stimuli related to oncogenesis, including many cytokines, viral products, oncoproteins as well as physical, oxidative and genotoxic stress. 4, 9, 11, 12 This activation involves the phosphorylation of IB, which is subsequently degraded in an ubiquitin-dependent step by the proteasome, thereby allowing the liberated NF-B dimer to translocate to the nuclear compartment. 1, 2 Within the nucleus, NF-B is involved in the coordinated expression of numerous target genes, for example, cytokines and chemokines, growth factors, antiapoptotic genes, cell adhesion molecules, proteolytic enzymes, angiogenic factors as well as procoagulatory molecules. 4, 9, 13 Phosphorylation of IB is achieved by a high molecular weight assembly kinase termed the IB kinase (IKK) complex. [14] [15] [16] Two kinase-active subunits have been cloned, which were named IKK-␣ and -␤. Genetic as well as cell culture studies suggest that IKK-␤ plays an essential role in NF-B activation by proinflammatory stimuli as well as in the subsequent inactivation of the IKK complex. 14, 16, 17 The function of IKK-␣ is less well characterized, although it has been implicated in specific signaling pathways as well as in proliferation and differentiation processes. 14, 15 An adaptor or scaffold protein named IKK-␥ has also been found, which may stabilize the complex or regulate the kinase activity. 14, 15 Recently, in several HD cell lines as well as ALL cells a dysregulation of IKK complex-associated signal transduction was detected with enhanced persistent activation of the IB kinases. 6, 18 In addition, association of the oncogenic protein Tax with IKK-␣ and -␤ leads in human T cell leukemia virus type-1 (HTLV-1) infected T cells to a persistent activation of these kinaseactive subunits. 19 The role of NF-B in acute myeloid leukemia (AML) is not yet clear. A preliminary study showed an upregulated cytokine expression in AML blasts and, in eight of 19 cases, an increased nuclear translocation of NF-B was detected. 20 The present study was designed to more thoroughly investigate the role of NF-B in AML, which is a heterogenous group of myeloid disorders. 21, 22 AML was defined according to the classification of the French-American-British (FAB) committee. 21 We investigated the activation status of the NF-B system in myeloid blasts from bone marrow (BM) as well as peripheral blood (PB) in different types of AML (M1, M2, M4 and M5). A major point of interest was to characterize the activity level of the upstream IKK complex in these cells. Furthermore, the protein levels of IB-␣ and the IKK complex subunits IKK-␣ and -␤ were examined. Finally, AML blasts were cultured ex vivo and the effects of TNF or LPS as well as the proteasome inhibitor PSI on the NF-B system were investigated.
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Materials and methods
Harvest of AML blasts and control cells
For our analysis, bone marrow (BM) and peripheral blood (PB) aspirates were taken from patients with acute myeloid leukemia. AML was defined according to the classification of the French-American-British (FAB) committee by using the panoptical Pappenheim procedure and cytochemical methods such as peroxidase and esterase staining ( Table 1) . The disease status, ie de novo, newly diagnosed AML or sample at relapse, as well as the quality of sample (cryopreserved or freshly obtained) are indicated in Tables 1 or 3 , respectively. In addition, cytogenetic data are presented for the patients (Table 1 ). Morphological characterization was followed by flow cytometry as an additional method for the lineage assign- Table 1 Details of patients examined in this study Leukemia ment of malignant cells in acute leukemias (Table 2) . After diagnosis of acute myeloid leukemia, isolation of blasts was performed in the following manner: Ficoll separating solution (Seromed, Berlin, Germany) was carefully overlayered with the samples diluted 1:1 with PBS followed by centrifugation for 30 min at 400 g without braking. The platelet-rich plasma was discarded and the blast containing cell layer washed twice with PBS. As control, cells from BM or PB from healthy subjects were used. These were isolated in the same way as the AML blasts or treated by Ficoll/adherence to isolate monocytes. Furthermore, granulocytes were separated from whole blood using Polymorphprep (Nycomed Pharma Diagnostics, Oslo, Norway). After counting the isolated cells by SE9000 (Sysmex, Norderstedt, Germany), 3-5 × 10 6 cells were directly processed or stored at −80°C in 0.1 ml PBS with protease inhibitors (leupeptin, aprotinin, antipain, pepstatin A and chymostatin 7.5 g/ml each) and 5 mM phenylmethylsulfenylfluoride (PMSF) (Sigma, Deisenhofen, Germany). Informed consent was obtained from AML patients and healthy donors according to the rules of the Ethical Committee of the Technische Universität Mü nchen, Germany.
Flow cytometry
Immunophenotypic analysis of blast cells was performed by flow cytometry ( Table 2 ). The monoclonal antibodies (mAb) were conjugated directly with fluorescein isothiocyanate (FITC) or phycoerythrin (PE). The following mAb were purchased from Beckman Coulter (Krefeld, Germany): anti-CD33-FITC, anti-CD34-PE, anti-CD64-FITC, anti-CD65s-FITC and anti-CD117-PE. Other mAb were obtained from Becton Dickinson (Heidelberg, Germany): anti-CD4-PE, anti-CD13-PE, anti-CD14-PE, anti-CD15-FITC and anti-HLA-DR-PE. For intracellular staining Combi-IC mAbs were purchased from Caltag Laboratories (Hamburg, Germany): anti-MPO/CD3-FITC/PE, anti-MPO/CD22-FITC/PE as well as anti-MPO/lactoferrin-FITC/PE and anti-lysozyme-FITC. Isotypic controls were purchased from each of the relevant companies. White blood count was perfomed using a Coulter STKS analyzer (Beckman Coulter). The samples were prepared by labeling 5 × 10 5 cells with mAb for 10 min in the dark and subsequently undergoing a hypotonic lysis of red blood cells (FACS Lysing Solution; Becton Dickinson). The samples were pelleted and then resuspended in PBS. For the detection of intracellular antigens Fix & Perm Cell Permeabilization Kits (Caltag Laboratories) were used. The fluorescence was measured using a FACScan flow cytometer after calibration with CaliBRITE beads using the AutoCOMP software (Becton Dickinson). Ten thousand cells were measured for each determination. The gating procedure consisted of the identification of blasts according to their scatter profile and CD34 or CD117 expression. Surface expression in Ͼ20% and intracellular expression in Ͼ10% of the cells was defined as +.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared and analyzed as described previously 23 with the following modifications: frozen cells (see above) were thawed by addition of an equal volume of 2× buffer A (1× buffer A: 0.1% Nonidet P-40; 10 mM Hepes, pH 7.9; 10 mM KCl; 1.5 mM MgCl 2 ; 0.5 mM dithiothreitol (DTT); 300 mM sucrose) and all steps were performed using 10× protease inhibitors (1 × inhibitors are as follows: 0.75 g/ml each of pepstatin, antipain, chymostatin, aprotinin, leupeptin; 0.5 mM PMSF). The prototypic immunoglobulin -chain oligonucleotide was used as a probe and labeled by annealing of complementary primers followed by primer extension with the Klenow fragment of DNA polymerase I (Roche Diagnostics, Mannheim, Germany) in the presence of ␣-32 P-dCTP (Ͼ3000 Ci/mmol; NEN Life Science Products, Brussels, Belgium) and deoxynucleoside triphosphates (Roche Diagnostics). Equal amounts of nuclear proteins were incubated with radiolabeled DNA probes (approximately 10 ng; 10 5 c.p.m.) for 30 min at room temperature in 20 l binding buffer (20 mM Hepes, pH 7.9; 50 mM KCl; 1 mM DTT; 0.5 mM EDTA; 5% glycerol; 1 mg/ml BSA; 0.1% Nonidet P-40; 50 ng/l poly(dI-dC)). Samples were run in 0.25× TBE buffer (10× TBE is as follows: 890 mM Tris; 890 mM boric acid; 20 mM EDTA, pH 8.0) on nondenaturing 4% polyacrylamide gels. An equal quality of nuclear extracts was also examined by monitoring the binding of proteins to an Oct-1 consensus oligonucleotide. Gels were dried and analyzed by autoradiography followed by densitometry.
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Supershift analysis
The nuclear extracts were incubated with 2 l of appropriate TransCruz gel supershift antibodies (Santa Cruz Biotechnology, Heidelberg, Germany) per 20 l of reaction volume in binding buffer at 4°C for 2 h prior to addition of the radioactively labeled probe. The following rabbit polyclonal supershift antibodies were used: anti-p50, anti-p65, anti-p52, antic-Rel and anti-RelB. This incubation step was followed by EMSA as described above.
Panoptical staining according to Pappenheim
Initially, the dried BM and PB blood smears were dehydrated for 2 min in water-free methanol to remove the lipid components, especially from the BM samples. Dehydration and fixation in methanol was followed by staining with May-Grü nwald-Giemsa. After air drying, the cells were photographed on a Leitz DMR photomicroscope (Leica, Wetzlar, Germany).
Immunofluorescence
Immunofluorescence was performed as described earlier. 23 Blood smears were made from fresh BM and PB aspirates, and fixed for 5 min in 3.7% formaldehyde. After 5 min washing in PBS, the slide was incubated in 0.1% BSA in PBS for 30 min to block unspecific antibody binding. The specimens were permeabilized for 10 min by 0.1% NaN 3 reagent (Coulter Immunotech, Hamburg, Germany), followed by incubation with ␣-p65MAb (1:250 dilution; Roche Diagnostics) overnight at 4°C or 1 h at room temperature. Blood smears were subsequently washed 3 × 5 min in PBS and then incubated with biotinylated anti-mouse IgG (H+L), (Vector Laboratories, Camon, Wiesbaden, Germany) for 60 min at room temperature. The smears were again washed for 3 × 5 min in PBS and incubated with streptavidin-Cy3 (Dianova, Hamburg, Germany) for 30 min at room temperature. After washing for 5 min in PBS, the slide was covered with Vectashield (Camon) mounting medium for fluorescence. Microphotographs were taken on a Leitz DMR photomicroscope (Leica) equipped with epifluorescence optics. To examine the red Cy3 fluorescence an excitation filter at 550 nm and an emission filter at 575 nm were used.
Kinase assay
Cytosolic proteins were isolated and equal amounts were subjected to immunoprecipitation (IP) in TNT buffer (200 mM NaCl; 20 mM Tris-HCl, pH 7.5; 1% Triton X-100; 1 mM DTT; 0.5 M 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF); leupeptin, antipain, aprotinin, pepstatin A and chymostatin 0.75 g/ml each; Sigma) as described. 17 IP was carried out for 2 h at 4°C with 1 g of antibody against IKK-␣ or -␤ (Santa Cruz Biotechnology, QED Bioscience, San Diego, CA, USA), respectively, and 35 l of 6% protein A-agarose (Roche Diagnostics). The kinase reaction was performed in kinase buffer (20 mM Hepes, pH 8.0; 10 mM MgCl 2 ; 100 M Na 3 VO 4 ; 20 mM ␤-glycerophosphate; 50 mM NaCl; 2 mM DTT; 0.5 M AEBSF; leupeptin, antipain, aprotinin, pepstatin A and chymostatin 0.75 g/ml each) for 30 min at 30°C in the presence of 5 Ci ␥-32 P-ATP (NEN Life Science Products) and 500 ng of the substrate GST-IB-␣ (Santa Cruz Biotechnology). Proteins were analyzed on 12.5% polyacrylamide gels (0.1% SDS), dried and visualized by autoradiography. Data were analyzed by densitometry, values obtained were averaged for each patient and fold induction was calculated above control.
Polyacrylamide gel electrophoresis and Western blot analysis
The same amount of cytosolic protein was applied in each lane and electrophoresis was performed with 12.5% polyacrylamide gels (0.1% SDS) and blotted as previously described. 17 Protein loading was monitored by Ponceau S staining. The following antibodies were used: anti-IB-␣, anti-IKK-␣ and -␤ (Santa Cruz Biotechnology, QED Bioscience) as well as anti-␣-actin (Sigma). The proteins were visualized on X-ray film using the Western blot Chemiluminescent Reagent Plus (NEN Life Science Products) and analyzed by densitometry. The protein size was confirmed by molecular weight standards (Amersham, Braunschweig and BioRad, Munich, Germany).
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Cell culture conditions THP-1 human monocytic cells (DSMZ, Braunschweig, Germany) were maintained in suspension in RPMI-1640 (Glutamax-1, low endotoxin; Seromed) containing 7% fetal calf serum (FCS, Myoclone super plus, low endotoxin; BioWhittaker, Walkersville, MD, USA), 100 U/ml penicillin and 100 g/ml streptomycin (GibcoBRL, Eggenstein, Germany) as described. 24 For the experiments, the cells were plated at a density of 3 × 10 6 per well in six-well culture dishes. AML blasts isolated as described above were cultured in the same manner. LPS (E. coli 0111:B4) and TNF were purchased from Sigma and the proteasome inhibitor PSI from Calbiochem-Novabiochem (Bad Soden, Germany). Endotoxin contamination was screened by the limulus amoebocyte lysate assay (BioWhittaker) and only reagents with an endotoxin content of Ͻ10 pg/ml were used in the experiments. A potential toxicity of the cell culture conditions applied was monitored by cell morphology and count, trypan blue dye exclusion and the WST-1 cell toxicity test (Roche Diagnostics).
Data analysis
Statistical significance was determined by the two-tailed Student's t-test (differences between subtypes as well as correlation of CD markers with NF-B activity) or Gauss test (IB-␣ and IKK-␣). A P-value Ͻ0.05 was considered as significant. Data are expressed as mean ± s.d.
Results
NF-B activation in AML
The initial experiments examined the activation status of NF-B in AML. Blast cells were isolated from BM and PB from AML patients. As shown in Table 1 , the patient samples at diagnosis and before isolation contained usually more than 60% blasts as determined by morphological analysis. Further characteristics (cytogenetic and immunophenotypic data) of the AML patients are presented in Tables 1 and 2 . As control BM and PB samples were used from healthy persons (see Materials and methods). The activation of NF-B was determined by EMSA. In all of the M4 and M5 cases examined and in the majority of the M1-and M2-subtype AML samples, a marked activation of NF-B compared to the controls was found in both de novo, newly diagnosed AML and samples at relapse which was comparable in both groups (Figure 1a , Tables 1 and 3) . A semiquantitative analysis of the data is shown in Table 3 . Essentially, the same results were observed regardless of whether cryopreserved or freshly obtained samples were examined, respectively (Table 3 , data not shown). Differences in the extent of NF-B activation between M4/M5 or M1/M2 will be further addressed in Figure 5 . In two of eight M1 and in two of eight M2 patient samples no increased NF-B activation was detected (Table 3) . NF-B activation was detected in blast cells regardless of whether deriving from BM or PB (Figure 1a) . Supershift analysis identified p50 and p65 subunits in the myeloid blast nucleus and suggested the presence of prototypical p50/p65 heterodimers as well as p50 and p65 homodimers (Figure 1b) . A RelB band was additionally found in two cases of M1/M2 AML (Figure 1c, Table 3 ).
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Figure 1
NF-B activation in AML. Nuclear extracts were prepared from bone marrow (BM) or peripheral blood (PB) blasts (subtype M4) as well as control cells (Co) and analyzed by EMSA (a, Table 1 : patients 17 and 18). Supershift analysis was performed on nuclear extracts from bone marrow of M5-(b, patient 29) and M1-type (c, patient 2) AML. For this purpose, nuclear extracts were preincubated with polyclonal antibodies directed against p50, p65, p52, c-Rel and RelB. Arrows mark the positions of the bands shifted by preincubation with anti-p50 or anti-p65, respectively. The RelB band is marked by an arrowhead. *, Longer exposure of the same supershift to visualize the RelB band. No Ab, no antibody was added for preincubation. The brackets indicate NF-B binding.
A significantly higher (P Ͻ 0.05) level of NF-B activity (analyzed by densitometry, fold induction above control, mean ± s.d.) was found in CD4-, CD64-and CD65s-positive AML blasts in comparison to the relevant negative specimens (CD4 + : 5.84 ± 2.38, CD4 Tables 2 and 3) .
Nuclear localization of NF-B in AML blasts
The following experiments were performed to demonstrate that the increased level of NF-B activation can indeed be attributed to AML blasts. Blood smears from peripheral AML and normal blood were used to demonstrate this. The morphology of the cells was initially established using Pappenheim and esterase staining (Figure 2a and b) . Blood smears from the same patient sample were then examined with immunofluorescence techniques to monitor for nuclear NF-B using the antibody ␣-p65MAb. A clear fluorescence signal was found in the nucleus of blasts (Figure 2a , Table 3 ) whereas only a weak one was seen in monocytes and granulocytes derived from blood of healthy donors (Figure 2b and data not shown). Increased nuclear NF-B binding activity observed by EMSA was therefore confirmed by a morphological approach and localized to blast cells.
Increased IKK complex activity in AML
The next step was carried out to examine the question of whether the NF-B activation observed in AML is a result of upstream IKK complex activation. To investigate this, cytosolic extracts from blasts and control cells were analyzed by kinase assay. After precipitation with either anti-IKK-␣ or anti-IKK-␤ the level of IKK activity was clearly seen to be increased in AML in comparison to the controls, as shown by GST-IB-␣ phosphorylation (Figure 3a) . A semiquantitative data analysis of the kinase assays is depicted in Table 3 . An increased IKK activation was observed in BM as well as in PB from the AML patients (Figure 3b ).
Levels of IB and IKK in AML blast cells
The protein levels of IB-␣, IKK-␣ and IKK-␤ in AML patients were next investigated. To this end, cytosolic extracts of AML and control cells were subjected to Western blot analysis. Interestingly, the concentration of the NF-B inhibitory protein, IB-␣, which is an NF-B target gene, was slightly higher (2.24 ± 1.52-fold induction, mean ± s.d., n = 28, P Ͻ 0.05, patients, as depicted in Table 3 ) in the AML samples in comparison to the controls (Figure 4a) . THP-1 cell extracts were used as a positive control, and showed degradation of IB-␣ after 60 min of LPS (1 g/ml) stimulation (Figure 4a ). Comparable IKK-␣/␤ as well as ␣-actin protein levels were detected in blast cells relative to controls as well as between different types of AML (M2, M4, M5; M1 data not shown) as demonstrated in Figure 4 and Table 3. For example, the level of IKK-␣ was negligibly (1.43 ± 1.09-fold) higher in AML cytosolic extracts compared to controls (mean ± s.d., n = 25, no statistical significance, patients as indicated in Table 3 ). The increased kinase activity shown in Figure 3 is therefore due to an increase in the activity of the IKK complex rather than a change in the absolute amount of kinase subunits present.
Differences in NF-B activation between FAB subtypes of AML
During our study the question arose whether there are differences in the extent of NF-B activation between various types of AML. To address this question, FAB subtypes were directly compared in EMSA and kinase assay. When the monocytedifferentiated AMLs, M4/M4Eo (eight patients examined) and M5 (seven cases), were analyzed by EMSA, no prominent distinction was found (Figure 5a, Table 3, see below) . A similar result was obtained by comparing AML FAB types M1 (eight 
The numbers refer to patients of Table 1 . Quality of sample: c, cryopreserved probe; f, freshly obtained cell sample; b, both fresh and cryopreserved sample. EMSA, data were analyzed densitometrically for NF-B activation and fold increase above control was calculated: −, no increase; +, Ն1.2-and Ͻ3-fold increase; ++, Ն3-and Ͻ5-fold increase; +++, Ն5-fold increase; n.d., not determined. ᭛, sample was used for cell culture experiments. Supershift: identified subunits are depicted. Kinase assay: data were analyzed densitometrically for activation of the IKK complex and fold increase is indicated as described above. Phospho-WB, Western blot analysis with an antibody against phosphorylated IB-␣. Western blot: the protein levels of IB-␣ and IKK-␣ were analyzed densitometrically and fold increase above control is depicted as described for EMSA. Fluorescence: *, nuclear p65 was detected by immunofluorescence; no, no detection of nuclear p65.
patients) and M2 (eight cases) (Figure 5b ). In contrast, the opposition of monocyte-differentiated vs undifferentiated or granulocyte-differentiated AMLs showed a clear difference in the degree of NF-B activation, with M4/M5 grades exhibiting a more extensive signal (Figure 5c, upper panel) . The level of NF-B activity (analyzed by densitometry, fold induction above control, mean ± s.d.) was significantly higher (P Ͻ 0.05) in M4 samples (6.21 ± 3.08, n = 8, patients as depicted in Table 3 ) compared to M1 (2.02 ± 1.31, n = 8, all M1 patients) or M2 (2.79 ± 1.96, n = 8, all M2 cases), respectively, as well as in M5 samples (6.51 ± 2.07, n = 7, patients as indicated in Table 3 ) compared to M1 or M2 (P Ͻ 0.01). Analysis of the samples by kinase assay showed a similar result, with M4/M5 graded AML patients demonstrating a higher kinase activity than M1/M2 (Figure 5c , lower panel), although statistical significance (P Ͻ 0.05) was only obtained when M5 samples were compared vs M1/M2 (fold induction, mean ± s.d., M1:
Leukemia 2.43 ± 1.41; M2: 2.00 ± 1.22; M4: 4.25 Ϯ 2.63; M5: 6.0 ± 3.13; all subtype patients as depicted in Table 3 ).
Effect of TNF and LPS as well as PSI on the NF-B system in cultured blasts
A further point of interest was whether the activation status of the IKK complex as well as NF-B in AML blasts could be further influenced by exogenous factors. Blasts from PB were isolated and cultured as described in Materials and methods. Following culture in endotoxin-free medium for 24 h, the blasts were stimulated with either 1.6 ng/ml TNF for 5 min or 1 g/ml LPS for 30 min. The stimulated cells were subsequently harvested and cytosolic as well as nuclear extracts were isolated. As seen in Figure 6a , kinase assays revealed a further increase of IKK activity in cultured blasts following
Figure 2
Nuclear localization of NF-B in AML blast cells. Blood smears from peripheral AML blood (a) and normal blood (b) were analyzed by immunofluorescence with ␣-p65MAb. In (a) a significant p65 staining can be found in the nucleus of both blasts depicted. In (b) a relatively weak staining of the nucleus of a control granulocyte and monocyte is shown. Note that cytoplasmic staining could be detected in both blasts and normal cells. Additionally, Pappenheim and esterase staining were performed. All smears in (a) are from the same M5 patient sample (patient 27), and those in (b) are from one control healthy donor.
Figure 3
IKK activity is increased in AML. Cytosolic extracts from blasts and monocytes (Co) were immunoprecipitated with an antibody against the respective IKK subunit (IKK-␣ or IKK-␤) followed by kinase assay using GST-IB-␣ as substrate. analysis suggested a constant loading of protein (Figure 6b) . In subsequent experiments the question was investigated whether NF-B activation in AML blasts could be modulated by specific inhibitors. The experiments were performed in the same manner as described above, except that the blasts were preincubated for 1 h with the proteasome inhibitor PSI (10 M) prior to stimulation with TNF. EMSA as well as Western blot analysis demonstrated that the NF-B activation/IB-␣ degradation observed in AML blasts could be inhibited by PSI (Figure 6c) . These experiments were performed with four specimens (patients 23, 24, 31, 32) and NF-B was inhibited by PSI in each of the experiments performed.
Discussion
Several lines of defense prevent the living organism from developing cancer, including processes of innate and adaptive immunity, antiproliferative transcriptional programs as well as NF-B activation in different FAB subtypes of AML. Nuclear extracts of different AML types were analyzed by EMSA and kinase assay (patients 2, 11, 17 and 27) . EMSA was used to compare NF-B activation between M4-and M5-type (a), M1-and M2-type (b) as well as M1-and M5-type (c, upper panel) AML. In this case cytosolic extracts were also immunoprecipitated with an antibody against IKK-␤ followed by kinase assay using GST-IB-␣ as substrate (c, lower panel). Co, control cells from BM or PB, respectively. Brackets indicate NF-B binding.
apoptosis. 4, 25, 26 If one of these protective mechanisms is defective or dysregulated malignancy can occur. This study demonstrated an increased level of activated NF-B in the nucleus of AML blast cells deriving from a BM as well as PB environment, consistent with earlier studies detecting nuclear NF-B in an albeit small amount of AML samples as well as AML stem cells. 20, 27, 28 Similarly, in several other forms of cancer an elevated level of NF-B activity has been detected in primary cells or cell lines derived from several hematopoetic diseases including childhood acute lymphoblastic leukemia (ALL) and Hodgkin's disease (HD) as well as several types of solid tumors. [4] [5] [6] 29 The BCR-ABL oncoprotein involved in chronic myelogenous leukemia as well as ALL is known to activate NF-B by two mechanisms, through a relatively weak stimulation of nuclear translocation and targeting of the transcriptional activation domain. 4 Under physiological conditions, constitutively activated NF-B has been observed only in mature B cells and neurons. 4, 9 In B cells, this transcription factor has a role in ensuring cell survival, and thereby cell proliferation, and it was speculated that
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Figure 6
Effect of TNF and LPS as well as PSI on the NF-B system in cultured blasts. Isolated blasts from PB were cultured for 24 h and stimulated with TNF (1.6 ng/ml, 5 min) or LPS (1 g/ml, 30 min). Cytosolic extracts were immunoprecipitated with anti-IKK-␣ antibody and kinase assays were performed using GST-IB-␣ as substrate (a). The levels of IB-␣, IKK-␣ IKK-␤ and ␣-actin were analyzed in cytosolic extracts by Western blotting (b) (patient 23 in a and b). (c) The blasts were preincubated with the proteasome inhibitor PSI for 1 h followed by stimulation with TNF (1.6 ng/ml, 5 min). Nuclear extracts were analyzed by EMSA and cytosolic extracts were examined by Western blot for the presence of IB-␣, IKK-␣ and ␣-actin (patient 31).
this protects these cells from proapoptotic cytokines in inflamed areas. 4, 9 At present it is unclear whether the presence of activated NF-B in the nucleus of cancer cells represents a general hallmark for processes of malignancy, since only a limited number of tumor types have been investigated in this respect. 4 Nevertheless, it is tempting to speculate that NF-B as a 'proinflammatory transcription factor' represents a molecular link explaining why chronic inflammation provides a platform for the development of malignancy. 30, 31 Additional functional aspects, eg processes regarding apoptosis, will be further outlined below.
The NF-B activation in myeloid blast cells was associated with increased IKK activity in our experiments which could be further stimulated by TNF or LPS, which contrasts with experiments using HD or ALL cells in which no further stimulation is observed using TNF or phorbol ester. 6, 18 Notably, proteasome inhibition in both ALL 6 and, as shown in our study, in AML primary cultures results in a hyperphosphorylated form of IB-␣, indicating activation of upstream kinases and it was speculated that constitutive NF-B activation is caused by ongoing signaling in these cells which would lead to persistent activation of IKK. Two mechanisms underlying constitutive NF-B activation were found in HD cells, namely persistently activated IKK and, in some cases, mutated IB-␣. 18, 32 In HTLV-1, Tax protein regulates the activity of the IKK complex. 19, 33 Elevated basal IKK activity and IB-␣ phosphorylation is also characteristic for Hs294T melanoma cells accompanied by increased basal melanoma growth stimulatory activity/GRO-␣ transcription. 34 Finally, NF-B activation by oncogenic Ras appears to be mediated by IKK-␣ and IKK-␤, while Raf-induced NF-B activation is solely dependent on IKK-␤. 35 The level of NF-B activation was higher in M4 or M5 cells, representing myelomonocytic or monocytic blasts, respectively, 21, 22 than in AML of early or granulocytic differentiation (M1/M2) in the presented study, which may indicate differentiation-associated distinctions in the signal transduction machinery and/or different molecular mechanisms underlying constitutive NF-B activation, similar to that described for HD. 18, 32 This is in contrast to the NF-B activation pattern observed in ALL, which does not display any subtype restriction. 6 Comparable to the results mentioned above, in our experiments the IKK complex activity was found to be higher in M4/M5-type AML than in M1/M2 cells. Interestingly, in M4/M5 cells an increased level of the NF-B regulated protein MMP-9 was found (data not shown), which may be involved in metastatic processes resulting in the migration of these leukemia cells to specific submucosal regions such as the gingiva. 36 Other NF-B target genes, eg associated with proliferation/differentiation or adhesion, may be differentially affected in various AML subtypes. 4, 36 In addition, it should be mentioned that when we correlated immunophenotypic and EMSA data, we found a significantly higher level of NF-B activity in blasts expressing CD4, CD64 and CD65s, which were found more frequently on M5 or M4 AML specimens in our study.
Both p50 and p65 were found in the nucleus of myeloid blasts similar to ALL, 6 indicating the presence of p50/p65 as well as homodimeric complexes. A significant level of nuclear NF-B p50 and p65 can also be found in the unstimulated THP-1 cell line (data not shown), which is derived from a patient suffering from acute monocytic leukemia. 37 It should be mentioned that varying patterns of NF-B subunit composition can be observed in different tumors, eg p50/p65 and p50/c-Rel as well as p50 homodimers in HD 18, 32, 38 or mainly p50, p52 and Bcl-3 in breast cancer. 39 Of note was the detection of additional RelB subunits in two cases of M1/M2 AML in our experiments.
The levels of the NF-B inhibitor protein IB-␣ were upregulated in AML. This is likely to be due to the increased presence of functional nuclear NF-B, since the IB gene is targeted by this transcription factor, 9 similar to IL-1␤ and -6, also found to be elevated in AML cells as shown earlier. 20 On the other hand, the increased amount of IB appears not to be sufficient to neutralize the increased level of activated NF-B dimers since a significant amount was visualized in the nucleus when we used immunofluorescence techniques, thus confirming our shift data. In contrast, in ALL cells and in some cases of HD an increased rate of IB-␣ degradation was found associated with constitutively active NF-B. 6, 18 In addition, in several cell lines deriving from HD patients point mutations were detected in the IB-␣ gene leading to C-terminally truncated proteins unable to bind to p65. 18, 32, 40 'Activate NF-B or die' was the paradigmatical phrase postulated recently in a review elucidating the role of NF-B in apoptosis, and in fact proved to be true in most experimental conditions studied. 26, 41 Activated NF-B was suggested to be a key regulator that connects the execution of the apoptotic program with an interpretation of the functional state of the cell's protein expression machinery. 26, 41 In the case of ALL it was proposed that general constitutive activation of NF-B in ALL serves as an important switch that ensures survival of ALL cells either by blocking apoptosis or by enhancing proliferation. 6 The anti-apoptotic properties of NF-B are likely to be at least partly due to the induction of antiapoptotic genes (eg manganese superoxide dismutase, the zinc finger protein A20, the Bcl-2 homolog A1/Bfl-1, IAP-and TRAF-related molecules) or to antagonizing caspase-8 activation and p53 function. 4, 26, 41 Primary leukemia cells displayed resistance towards induction of apoptosis by death-inducing ligands or drugs used for chemotherapy such as doxorubicin, which is a major reason for failure of anticancer treatment. 42 Antagonization of NF-B activity partially restored apoptosis sensitivity: eg inhibition of NF-B by the proteasome inhibitor LLnL led to a strong increase in sensitivity to apoptosis mediated by TRAIL, CD95 or TNF-receptor in both ALL and AML cells. 42 In our study the relatively specific proteasome inhibitor PSI significantly inhibited the NF-B system in myeloid blasts. Taken together these data indicate that inhibition of the multicatalytic proteasome complex, or other means to reduce NF-B activity such as antisense/decoy oligonucleotides, 43 peptides 44 or systemic small molecule inhibitors 4,45 could represent adjuvant therapeutical concepts (eg to overcome apoptosis resistance) to support chemotherapy, especially when treating AML with an unfavorable genetic karyotype, which is quite often resistant to regular chemotherapy, eg when anticipating transplantation procedures. 46 In conclusion, our study demonstrated an increased level of IKK activity in AML blasts derived from both BM and PB. This was associated with NF-B activation with higher levels in FAB subtypes M4/M5 compared to M1/M2. Dysregulation of NF-B in AML may lead to the increased expression of NF-B regulated genes coding for antiapoptotic proteins, cytokines and proteases in myeloid blast cells. Therefore, the NF-B system may represent a target for adjuvant therapeutical strategies, eg in the support of chemotherapy, to combat AML.
